» Articles » PMID: 32410694

Long-term Safety and Tolerability of Atabecestat (JNJ-54861911), an Oral BACE1 Inhibitor, in Early Alzheimer's Disease Spectrum Patients: a Randomized, Double-blind, Placebo-controlled Study and a Two-period Extension Study

Overview
Date 2020 May 16
PMID 32410694
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer's disease (AD). The long-term safety and effect of atabecestat on cognitive performance in participants with predementia AD in two phase 2 studies were assessed.

Methods: In the placebo-controlled double-blind parent ALZ2002 study, participants aged 50 to 85 years were randomized (1:1:1) to placebo or atabecestat 10 or 50 mg once daily (later reduced to 5 and 25 mg) for 6 months. Participants entered ALZ2004, a 12-month treatment extension with placebo or atabecestat 10 or 25 mg, followed by an open-label phase. Safety, changes in CSF biomarker levels, brain volume, and effects on cognitive performance were assessed.

Results: Of 114 participants randomized in ALZ2002, 99 (87%) completed, 90 entered the ALZ2004 double-blind phase, and 77 progressed to the open-label phase. CSF Aβ fragments and sAPPβ were reduced dose-proportionately. Decreases in whole brain and hippocampal volumes were greater in participants with mild cognitive impairment (MCI) due to AD than in preclinical AD, but were not affected by treatment. In ALZ2004, change from baseline in RBANS trended toward worse scores for atabecestat versus placebo. Elevated liver enzyme adverse events reported in 12 participants on atabecestat resulted in dosage modification and increased frequency of safety monitoring. Treatment discontinuation normalized ALT or AST in all except one with pretreatment elevation, which remained mildly elevated. No case met ALT/AST > 3× ULN and total bilirubin > 2× ULN (Hy's law).

Conclusion: Atabecestat was associated with trend toward declines in cognition, and elevation of liver enzymes.

Trial Registration: ALZ2002: ClinicalTrials.gov, NCT02260674, registered October 9, 2014; ALZ2004: ClinicalTrials.gov, NCT02406027, registered April 1, 2015.

Citing Articles

Therapeutic agents for Alzheimer's disease: a critical appraisal.

Weinstock M Front Aging Neurosci. 2024; 16:1484615.

PMID: 39717349 PMC: 11663918. DOI: 10.3389/fnagi.2024.1484615.


Evaluation of hydrazone and -acylhydrazone derivatives of vitamin B6 and pyridine-4-carbaldehyde as potential drugs against Alzheimer's disease.

Bartolic M, Matosevic A, Marakovic N, Busic V, Roca S, Vikic-Topic D J Enzyme Inhib Med Chem. 2024; 39(1):2431832.

PMID: 39654394 PMC: 11633425. DOI: 10.1080/14756366.2024.2431832.


Secretase promotes AD progression: simultaneously cleave Notch and APP.

Yang K, Zhang J, Feng M, Yao K, Liu Y, Zhou M Front Aging Neurosci. 2024; 16:1445470.

PMID: 39634655 PMC: 11615878. DOI: 10.3389/fnagi.2024.1445470.


Sertraline as a Multi-Target Modulator of AChE, COX-2, BACE-1, and GSK-3β: Computational and In Vivo Studies.

Arfeen M, Mani V Molecules. 2024; 29(22).

PMID: 39598743 PMC: 11596569. DOI: 10.3390/molecules29225354.


Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.

Ritchie M, Raman R, Ernstrom K, Wang S, Donohue M, Aisen P J Prev Alzheimers Dis. 2024; 11(6):1563-1571.

PMID: 39559869 PMC: 11573807. DOI: 10.14283/jpad.2024.157.


References
1.
Prados F, Cardoso M, Leung K, Cash D, Modat M, Fox N . Measuring brain atrophy with a generalized formulation of the boundary shift integral. Neurobiol Aging. 2014; 36 Suppl 1:S81-90. PMC: 4288791. DOI: 10.1016/j.neurobiolaging.2014.04.035. View

2.
Egan M, Kost J, Tariot P, Aisen P, Cummings J, Vellas B . Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018; 378(18):1691-1703. PMC: 6776074. DOI: 10.1056/NEJMoa1706441. View

3.
Hardy J, Higgins G . Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256(5054):184-5. DOI: 10.1126/science.1566067. View

4.
Brashear H, Ketter N, Bogert J, Di J, Salloway S, Sperling R . Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. J Alzheimers Dis. 2018; 66(4):1409-1424. DOI: 10.3233/JAD-180675. View

5.
Yan R . Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016; 5:13. PMC: 4944430. DOI: 10.1186/s40035-016-0061-5. View